---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-108192"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:28:18.623755+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics Q3 update: SYMON-II 50% enrolled, $3.08M cash, needs $20M more by 2027

## Summary
- Q3 cash $3.08M; stockholders' equity $3.69M. Raised $3.85M in April and $4.5M PIPE in October.
- SYMON-II pivotal trial patient enrollment ~50% completed; sample testing expected late 2026 subject to financing.
- Company expects to need at least $20M additional capital by end of FY2027 to fund operations and FDA submission.
- Amended agreements with SanyoSeiko to expand manufacturing role for Symphony platform commercialization.
- No revenue reported; pre-commercial stage; Symphony IL-6 test targets sepsis diagnostics, market projected at $1.8B by 2030.

## SEC filing metadata
- accession: 0001213900-25-108192
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390025108192/0001213900-25-108192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390025108192/ea0264778-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-108192
- JSON: https://secwatch.observer/filing/0001213900-25-108192.json
- Plain text: https://secwatch.observer/filing/0001213900-25-108192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.